泰林生物
(300813)
| 流通市值：22.68亿 | | | 总市值：36.14亿 |
| 流通股本：7605.11万 | | | 总股本：1.21亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 134,971,542.57 | 197,925,160.45 | 210,343,842.89 | 264,872,528.62 |
| 交易性金融资产 | 2,100,542.69 | - | - | - |
| 应收票据及应收账款 | 49,034,637.68 | 46,920,018.79 | 44,473,461.2 | 43,546,552.81 |
| 应收账款 | 49,034,637.68 | 46,920,018.79 | 44,473,461.2 | 43,546,552.81 |
| 应收款项融资 | 8,670,714.63 | 7,553,636.6 | 9,209,827.65 | 9,837,937.21 |
| 预付款项 | 6,024,733.49 | 2,653,475.16 | 3,095,868.41 | 3,779,076.27 |
| 其他应收款合计 | 9,377,913.27 | 11,521,981.36 | 10,046,756.44 | 8,485,615.12 |
| 存货 | 153,639,950.2 | 141,538,974.71 | 141,018,169.49 | 144,134,014.09 |
| 合同资产 | 4,217,771.55 | 8,118,693.85 | 9,390,390 | 9,008,033.49 |
| 其他流动资产 | 177,154,730.6 | 173,540,322.44 | 187,295,324.75 | 149,098,120.91 |
| 流动资产合计 | 545,192,536.68 | 589,772,263.36 | 614,873,640.83 | 632,761,878.52 |
| 非流动资产: | | | | |
| 其他债权投资 | 55,263,397.26 | - | - | - |
| 长期股权投资 | 8,381,997.62 | 8,139,174.06 | 8,141,620.34 | 8,144,676.28 |
| 投资性房地产 | 8,627,278.81 | 8,703,202.05 | 8,699,475.37 | 8,774,709.79 |
| 固定资产 | 253,432,110.02 | 255,722,393.94 | 256,294,198.81 | 260,054,131.14 |
| 在建工程 | 5,161,172.41 | 6,325,657.78 | 8,012,272.07 | 6,656,387.04 |
| 无形资产 | 27,715,686.1 | 11,535,722.92 | 10,803,786.73 | 10,918,106.68 |
| 长期待摊费用 | 29,939,755.76 | 30,562,659.62 | 30,859,847.88 | 31,246,676.91 |
| 递延所得税资产 | 233,563.67 | 40,152.68 | 87,781.81 | 87,781.81 |
| 其他非流动资产 | 116,267.61 | 16,026,600 | 1,246,700 | 1,263,579.9 |
| 非流动资产合计 | 388,871,229.26 | 337,055,563.05 | 324,145,683.01 | 327,146,049.55 |
| 资产总计 | 934,063,765.94 | 926,827,826.41 | 939,019,323.84 | 959,907,928.07 |
| 流动负债: | | | | |
| 短期借款 | - | - | - | 3,669,656.41 |
| 应付票据及应付账款 | 15,378,794.85 | 15,003,337.38 | 13,497,537.39 | 15,194,299.97 |
| 应付账款 | 15,378,794.85 | 15,003,337.38 | 13,497,537.39 | 15,194,299.97 |
| 合同负债 | 85,515,627.35 | 73,214,300.59 | 74,197,818.99 | 76,580,599.71 |
| 应付职工薪酬 | 16,597,378.64 | 14,116,617.79 | 11,533,202.18 | 26,117,973.72 |
| 应交税费 | 1,640,570.62 | 2,190,838.53 | 2,243,880.71 | 4,578,096.22 |
| 其他应付款合计 | 17,920,205.44 | 6,327,862.86 | 7,527,023.86 | 6,235,446.87 |
| 其他流动负债 | 3,641,459.24 | 2,705,937.36 | 3,048,077.18 | 3,409,029.76 |
| 流动负债合计 | 140,694,036.14 | 113,558,894.51 | 112,047,540.31 | 135,785,102.66 |
| 非流动负债: | | | | |
| 递延所得税负债 | 3,225,150.58 | 3,054,070.83 | 3,393,283.59 | 3,393,283.59 |
| 非流动负债合计 | 3,225,150.58 | 3,054,070.83 | 3,393,283.59 | 3,393,283.59 |
| 负债合计 | 143,919,186.72 | 116,612,965.34 | 115,440,823.9 | 139,178,386.25 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 121,199,219 | 121,199,219 | 121,199,219 | 121,199,219 |
| 资本公积 | 411,261,023.32 | 409,249,442.39 | 420,507,953.91 | 420,507,953.91 |
| 减:库存股 | 11,174,000 | - | - | - |
| 盈余公积 | 27,628,568.73 | 27,628,568.73 | 27,628,568.73 | 27,628,568.73 |
| 未分配利润 | 241,229,768.17 | 252,137,630.95 | 254,242,758.3 | 250,714,603.67 |
| 归属于母公司股东权益合计 | 790,144,579.22 | 810,214,861.07 | 823,578,499.94 | 820,050,345.31 |
| 少数股东权益 | - | 0 | - | 679,196.51 |
| 股东权益合计 | 790,144,579.22 | 810,214,861.07 | 823,578,499.94 | 820,729,541.82 |
| 负债和股东权益合计 | 934,063,765.94 | 926,827,826.41 | 939,019,323.84 | 959,907,928.07 |
| 公告日期 | 2025-10-27 | 2025-08-29 | 2025-04-28 | 2025-04-28 |
| 审计意见(境内) | | | | 标准无保留意见 |